Edwards Lifesciences raised its full-year 2026 revenue growth guidance to 9%–11% following a Q1 earnings beat that topped analyst expectations. The company also lifted its TAVR segment growth outlook to 7%–9% and set adjusted EPS guidance of $2.95–$3.05 for the year. The upward revision signals management's confidence that demand for its heart valve products is accelerating.
A guidance raise — not just a beat — is the stronger signal here; it means Edwards sees the momentum continuing, not just a one-quarter fluke. The TAVR segment, which covers transcatheter heart valves, is Edwards' core growth engine, so lifting that specific target matters for the stock's long-term valuation. Medical device investors should note this as a positive read-through for the broader structural heart space, including competitors like Medtronic and Abbott.
Next Edwards Lifesciences earnings update: Q2 2026 results expected late July 2025. FDA approval timelines for next-gen TAVR devices remain an ongoing catalyst to monitor throughout 2025.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief